share_log

Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $30 Price Target

Benzinga ·  May 9 08:50

Wedbush analyst Robert Driscoll reiterates Arcus Biosciences (NYSE:RCUS) with a Outperform and maintains $30 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment